Generic Name: emricasan
Drug Class: NAFLD/NASH Medications
Approval Status: Experimental
Generic Version Available: No
Experimental Code: IDN-6556, PF-03491390
Emricasan (IDN-6556, PF-03491390) is a pan-caspase inhibitor developed by Idun Pharmaceuticals, which was acquired by Pfizer, and most recently acquired by Conatus Pharmaceuticals. Conatus partnered with Novartis in this Phase 2 clinical trial for treatment of non-alcoholic steatohepatitis (NASH).
Dosing Info: N/A
Last Reviewed: February 4, 2019